Genostar Expands Deal with Biopharma Merial To Help Hunt Pathogenic Virulence Factors

As part of an expanded deal, Genostar will provide an update to its Iogma software so that Merial, a Sanofi-Aventis/Merck joint venture, can accelerate its search for vaccines and treatments of bacterial infections in livestock and companion animals.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.